- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06063733
Development and Feasibility Testing of Digital Theory-based Pursed Lip Breathing in Stable Patients With COPD
The goal of this pre-post design clinical trial is to develop a digital, theory-based Pursed Lip Breathing intervention protocol software system installed on smartphones (DT-PLB) and to preliminarily evaluate its feasibility and effects in stable Chronic Obstructive Pulmonary Disease (COPD). The main objectives are:
- To develop a digital, theory-based Pursed Lip Breathing intervention protocol software system installed on smartphones for managing breathing exercises in stable COPD patients.
- To pilot the methodological procedures of the pre-post study.
- To determine the recruitment rate, retention rate, attrition rate, and software usage compliance during the subject recruitment and follow-up process of the pre-post study.
- To evaluate the perception and satisfaction of COPD patients using the DT-PLB.
- To preliminarily examine the effects of using the DT-PLB intervention on COPD patients, including the six-minute walking test, FEV1% predicted, FEV1/FVC, mMRC scale, COPD assessment test scale, and health points.
- To identify any potential adverse events associated with the implementation of DT-PLB.
Participants will perform the following tasks during the intervention:
- Register a personal account on the DT-PLB software.
- Acquire knowledge and skills related to Pursed Lip Breathing by watching instructional videos.
- Practice Pursed Lip Breathing for 10 minutes per session, three times daily for eight weeks, as per reminders and guidance provided by the software.
- Earn health points by completing specific actions as instructed.
- Optionally post individual texts on the peer forum for peer support within the DT-PLB software.
- Complete two outcome assessments as scheduled.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Houqiang Huang, Master
- Phone Number: +8618715799162
- Email: 21442584@stu.mmu.ac.uk
Study Locations
-
-
Sichuan
-
Luzhou, Sichuan, China, 646000
- The Affiliated Hospital of Southwest Medical University
-
Contact:
- Houqiang Huang, Master
- Phone Number: +8618715799162
- Email: 21442584@stu.mmu.ac.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosed with COPD satisfying GOLD criteria (Agusti, 2022) ;
- Being Chinese;
- Able to understand, speak, and hear;
- Clinically stable for at least three months prior to enrollment (Soler-Cataluna et al., 2018) ;
- The classification of GOLD grades for patients is mild, moderate, and severe, which means: FEV1/FVC<70%, FEV1>30%pre (Agusti, 2022) ;
- Participants who were mindful about the IT technology and known how to use a smartphone.
Exclusion Criteria:
- Impaired hand function causing inability to use the application;
- Have disorders in pleural effusion, pulmonary malignancy, heart diseases, stroke with sequels;
- Patients who have oral or nasal diseases cannot complete the exercise.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Digital PLB intervention
Participants will perform the following tasks during the intervention:
|
After registration, participants will watch an educational video on the developed software, covering the definition, benefits, and techniques of pursed lip breathing. Following this, participants will engage in pursed lip breathing interventions, guided by voice and animated instructions from the software. These sessions will occur three times daily (morning, afternoon, and night) for 10 minutes each, lasting for 8 weeks. After each session, participants can choose to post texts on a peer social forum for peer support. Fellow participants can give 'comments' or 'likes'. The principal researcher will oversee texts, peer comments, removing information containing personal data, medical recommendations, and negative comments. Additionally, participants can earn health points by performing specific actions (e.g., watching the educational video and practicing pursed lip breathing) on the software, encouraging their participation in related activities. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recruitment rate
Time Frame: From baseline (T1) to the completion of the 8-week intervention (T2)
|
The number of participants who participate in the study divided by the number of participants eligible for participation
|
From baseline (T1) to the completion of the 8-week intervention (T2)
|
|
Retention rate
Time Frame: From baseline (T1) to the completion of the 8-week intervention (T2)
|
The number of subjects who complete the study divided by the number of subjects who participate in the study
|
From baseline (T1) to the completion of the 8-week intervention (T2)
|
|
Attrition rate
Time Frame: From baseline (T1) to the completion of the 8-week intervention (T2)
|
The number of subjects who drop out after participation divided by the number of subjects who participate in the study
|
From baseline (T1) to the completion of the 8-week intervention (T2)
|
|
Software usage Compliance
Time Frame: Immediately after completion of the 8-week intervention
|
The compliance rate is one of compliance outcomes, reflecting the level of patient engagement in the intervention.
Overall compliance will be defined as the compliance averaged in all patients.
Compliance rate = (actual number of participation in the intervention/planned number of sessions)x 100%.
In addition, minutes-consuming recorded on the software for participants during the research will be used to complement outcome measures of compliance.
|
Immediately after completion of the 8-week intervention
|
|
Adverse events associated with the DT-PLB intervention
Time Frame: Immediately after completion of the 8-week intervention
|
In each DT-PLB session, the participants during the intervention will record whether they had any uncomfortable feelings
|
Immediately after completion of the 8-week intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
mMRC Dyspnea Scale
Time Frame: From baseline (T1) to the completion of the 8-week intervention (T2)
|
The Modified Medical Research Council (mMRC) Dyspnea Scale consists of five categories, ranging from 0 to 4, with higher scores indicating more severe breathlessness.
A score of 0 indicates no breathlessness during activities, while a score of 4 suggests breathlessness.
|
From baseline (T1) to the completion of the 8-week intervention (T2)
|
|
CAT scale
Time Frame: From baseline (T1) to the completion of the 8-week intervention (T2)
|
COPD assessment test (CAT)is a questionnaire-based tool that is commonly used to assess the impact of chronic obstructive pulmonary disease (COPD)on a patient's health status and quality of life.
It consists of eight questions that cover a range of symptoms, including cough, sputum production, breathlessness, chest tightness, and activity limitations.
Each question on the CAT is scored on a scale from 0 to 5, with a maximum possible score of 40.
A higher score indicates a greater degree of symptom severity and a poorer health status.
|
From baseline (T1) to the completion of the 8-week intervention (T2)
|
|
The System Usability Scale
Time Frame: Immediately after completion of the 8-week intervention (T2)
|
The system usability scale (SUS)is a standardized questionnaire that is used to evaluate the usability and user experience of a wide range of products, services, and systems.
It produces a score between 0 and 100, with higher scores indicating better usability and user experience.
The SUS has been validated and is widely used in both industry and research settings to evaluate the usability and user experience of a wide range of systems and products, including software applications, websites, and medical devices.
|
Immediately after completion of the 8-week intervention (T2)
|
|
Participants overall satisfaction
Time Frame: Immediately after completion of the 8-week intervention (T2)
|
Participants will be required to rate their satisfaction with this software intervention, with a 10-point numeric rating scale (NRS) , where "1" represents "very dissatisfied" and "10" means "very satisfied".
|
Immediately after completion of the 8-week intervention (T2)
|
|
Six-minute-walking test
Time Frame: From baseline (T1) to the completion of the 8-week intervention (T2)
|
The Six-Minute Walk Test is a commonly used measure of functional exercise
|
From baseline (T1) to the completion of the 8-week intervention (T2)
|
|
Pulmonary function index:FEV1%predicted, FEV1/FVC
Time Frame: From baseline (T1) to the completion of the 8-week intervention (T2)
|
FEV1%predicted stands for "forced expiratory volume in one second predicted" and is a measure of lung function. It represents the maximum amount of air that a person can forcefully exhale from their lungs in one second. FEV1%predicted is expressed as a percentage of the predicted value for someone with the same characteristics who does not have lung disease. FEV1/FVC is another measure of lung function, which represents the ratio of the amount of air that a person can forcefully exhale in one second (FEV1)to the total amount of air that they can exhale(forced vital capacity or FVC)over the course of a full exhalation. A low FEV1/FVC ratio indicates that the airways are obstructed or narrowed, which is a characteristic feature of COPD. |
From baseline (T1) to the completion of the 8-week intervention (T2)
|
|
Health points obtained by each participant performing formulated operations
Time Frame: Immediately after completion of the 8-week intervention
|
Health points are set based on consensus, obtained by operating actions on this software:
|
Immediately after completion of the 8-week intervention
|
Collaborators and Investigators
Investigators
- Principal Investigator: Houqiang Huang, Master, Manchster Metropolitan University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KY2023105
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Disease, Chronic Obstructive
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
University of LeicesterUniversity Hospitals, Leicester; University of StrathclydeRecruitingChronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Lung Disease | Chronic Obstructive Airway DiseaseUnited Kingdom
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on Digital pursed lip breathing intervention
-
Riphah International UniversityCompleted
-
Riphah International UniversityNot yet recruiting
-
Riphah International UniversityCompletedObese WomenPakistan
-
Ataturk UniversityNot yet recruiting
-
Riphah International UniversityCompleted
-
Universidade Federal do Rio de JaneiroCompletedChronic Obstructive Pulmonary DiseaseBrazil
-
Riphah International UniversityCompleted
-
Riphah International UniversityCompletedChronic BronchitisPakistan
-
Ondokuz Mayıs UniversityNot yet recruitingBreast Surgery | Breast Cancer | Postoperative Pain | Anxiety
-
Riphah International UniversityCompletedChronic Obstructive Pulmonary DiseasePakistan